Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

NeuroPace, Inc.

NPCENASDAQ
Healthcare
Medical - Devices
$14.09
$-0.03(-0.21%)
U.S. Market opens in 13h 16m

NeuroPace, Inc. Fundamental Analysis

NeuroPace, Inc. (NPCE) shows moderate financial fundamentals with a PE ratio of -21.62, profit margin of -21.47%, and ROE of -1.06%. The company generates $0.1B in annual revenue with strong year-over-year growth of 22.14%.

Key Strengths

Cash Position13.24%
PEG Ratio-1.64
Current Ratio5.28

Areas of Concern

ROE-1.06%
Operating Margin-16.34%
We analyze NPCE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -92.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-92.3/100

We analyze NPCE's fundamental strength across five key dimensions:

Efficiency Score

Weak

NPCE struggles to generate sufficient returns from assets.

ROA > 10%
-20.33%

Valuation Score

Excellent

NPCE trades at attractive valuation levels.

PE < 25
-21.62
PEG Ratio < 2
-1.64

Growth Score

Excellent

NPCE delivers strong and consistent growth momentum.

Revenue Growth > 5%
22.14%
EPS Growth > 10%
26.77%

Financial Health Score

Moderate

NPCE shows balanced financial health with some risks.

Debt/Equity < 1
3.72
Current Ratio > 1
5.28

Profitability Score

Weak

NPCE struggles to sustain strong margins.

ROE > 15%
-105.67%
Net Margin ≥ 15%
-21.47%
Positive Free Cash Flow
No

Key Financial Metrics

Is NPCE Expensive or Cheap?

P/E Ratio

NPCE trades at -21.62 times earnings. This suggests potential undervaluation.

-21.62

PEG Ratio

When adjusting for growth, NPCE's PEG of -1.64 indicates potential undervaluation.

-1.64

Price to Book

The market values NeuroPace, Inc. at 24.39 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

24.39

EV/EBITDA

Enterprise value stands at -31.05 times EBITDA. This is generally considered low.

-31.05

How Well Does NPCE Make Money?

Net Profit Margin

For every $100 in sales, NeuroPace, Inc. keeps $-21.47 as profit after all expenses.

-21.47%

Operating Margin

Core operations generate -16.34 in profit for every $100 in revenue, before interest and taxes.

-16.34%

ROE

Management delivers $-1.06 in profit for every $100 of shareholder equity.

-1.06%

ROA

NeuroPace, Inc. generates $-20.33 in profit for every $100 in assets, demonstrating efficient asset deployment.

-20.33%

Following the Money - Real Cash Generation

Operating Cash Flow

NeuroPace, Inc. generates limited operating cash flow of $-11.32M, signaling weaker underlying cash strength.

$-11.32M

Free Cash Flow

NeuroPace, Inc. generates weak or negative free cash flow of $-11.67M, restricting financial flexibility.

$-11.67M

FCF Per Share

Each share generates $-0.35 in free cash annually.

$-0.35

FCF Yield

NPCE converts -2.40% of its market value into free cash.

-2.40%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-21.62

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.64

vs 25 benchmark

P/B Ratio

Price to book value ratio

24.39

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.78

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

3.72

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.28

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.06

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.19

vs 25 benchmark

How NPCE Stacks Against Its Sector Peers

MetricNPCE ValueSector AveragePerformance
P/E Ratio-21.6228.25 Better (Cheaper)
ROE-105.67%780.00% Weak
Net Margin-21.47%-20122.00% (disorted) Weak
Debt/Equity3.720.30 Weak (High Leverage)
Current Ratio5.284.66 Strong Liquidity
ROA-20.33%-14687.00% (disorted) Weak

NPCE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NeuroPace, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-17.61%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

65.48%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

72.66%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ